Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (24311)	8/9/1998 8:42:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

From the 1997 Annual report: "Ligand has an extensive Phase II clinical program in larger patient populations, including breast cancer, lung and prostate cancer, psoriasis and actinic keratoses. These trials will determine future NDA tracks and are designed to provide physicians with valuable information about additional activity of the drugs." The next 16 months are going to be very busy with news releases. Hopefully, they will be positive news releases.